Prior authorization and coding verification — confirm CPT/ICD match policy (e.g., 86352)

Verify that the procedure and diagnosis codes submitted match the policy guidance (example covered code: CPT 86352 for cellular function assay). Confirm coverage criteria are met before ordering and billing; obtain prior authorization when payer rules require it for the covered indication.

• Covered CPT example: 86352 (cellular function assay involving stimulation and detection of biomarker such as ATP).
• Verify applicable ICD-10 diagnosis supports the intended indication (policy lists covered and not-covered diagnosis groups).
• Obtain prior authorization when required by payer rules for the covered indication.

Prior authorization recommended — due to inconsistent/insufficient evidence

Consider prior authorization for clinical use because evidence is inconsistent and insufficient to support many assay-directed management decisions; document the clinical rationale when requesting authorization.

• Policy states pooled evidence is limited for infection and poor for rejection identification, supporting prior authorization for clinical use when assay results will influence management.
• Provide clinical justification and supporting documentation when seeking authorization.

Prior authorization when used to adjust immunosuppression — include assay values and plan

If assay results will be used to adjust immunosuppression, obtain prior authorization and include the assay values and the planned management changes in the authorization request.

• One RCT used ImmuKnow-directed tacrolimus adjustments (reduce 25% if ATP <130 ng/mL; increase 25% if ATP >450 ng/mL) and recorded management decisions tied to assay values.
• Policy advises providing assay values and intended management plan when prior authorization is sought for therapy adjustments.

Prior authorization likely required for non‑FDA-cleared assays

Expect prior authorization or additional documentation for assays that are not FDA-cleared; provide clinical justification and lab accreditation information when requesting coverage.

• Policy notes some commercial panels (e.g., CMV T Cell Immunity Panel) have not been FDA-cleared and may require payer review.
• Indicate that high-complexity laboratory tests are performed in CLIA/CAP-accredited labs when relevant.

Prior authorization for post‑transplant immune monitoring — document transplant status and timing

When ordering assays for post‑transplant immune monitoring (risk stratification or prophylaxis decisions), include transplant status, timing relative to transplant, and intended use in the prior authorization or clinical documentation.

• Policy describes assay use at specific post-transplant time points (e.g., day +28 and +100 post-allo-HSCT; months 3, 6, 8, 10, 12 post-lung transplant) to guide prophylaxis/monitoring.
• Document transplant type, post-transplant day/month of testing, and whether result will inform prophylaxis duration or surveillance strategy.

Prior authorization — policy history contains no explicit requirements

No explicit prior authorization steps are specified in the policy history or administrative notes; refer to payer-specific prior authorization rules as needed.

• Policy history and administrative notes do not define provider prior authorization steps.

Prefer serial monitoring over single time‑point when guiding therapy

Prefer serial, individualized monitoring rather than relying on a single time‑point assay value when using assays to guide clinical decisions.

• Multiple authors state isolated ImmuKnow values lack diagnostic capacity and that individual serial monitoring may better inform immunosuppression changes.

Documentation required for therapy changes — baseline and serial assay documentation

When proposing immunosuppression changes based on assay results, document baseline clinical status and serial assay measurements, and record the rationale and planned dose adjustments.

• The Ravaioli RCT specified serial testing and predefined tacrolimus dose-change thresholds tied to ATP values; policy recommends stepwise documentation when adjustments are made.
• Include baseline status, each assay result with dates, and the management decision linked to those results.

Step therapy — none specified in policy

No step therapy rules are provided in this policy section; follow institution and payer protocols for stepwise treatment prior to assay‑directed management.

• Policy does not define mandatory step therapy algorithms.

Assay‑guided prophylaxis decisions — document results and prophylaxis plan

Use CMV-specific assays to support individualized antiviral prophylaxis decisions, and document assay results and corresponding changes in prophylaxis duration or surveillance.

• Studies described use QuantiFERON-CMV and ImmuKnow around prophylaxis cessation (e.g., 6 months post‑lung transplant) to explore individualized discontinuation of prophylaxis.
• Document assay type, quantitative thresholds used, timing relative to prophylaxis cessation, and planned monitoring of CMV DNAemia.

Step therapy — no requirements described

No step therapy requirements are described in these policy chunks; apply local clinical care pathways and payer rules.

• Policy text contains no mandated step therapy sequences.

Clinical indication documentation — state purpose is adjudicating over‑immunosuppression

Document that ImmuKnow is being used to adjudicate potential over‑immunosuppression in transplant recipients with comorbid infection or cancer to meet the medically necessary indication.

• Policy states ImmuKnow is medically necessary specifically to adjudicate over‑immunosuppression in transplant recipients with co‑morbid infection or cancer.
• Include the clinical context (infection or cancer) in the request and medical record.

Document timing and serial measurements — record pre/post‑transplant schedule

Document timing of serial ImmuKnow measurements relative to transplant and clinical events; studies use pre‑transplant and multiple post‑transplant time points (e.g., days 7,14,21,42 and months 3,6,12).

• De Paolis collected samples pre-transplant and at days 7, 14, 21, 42 and months 3, 6, 12; other studies similarly used serial measurements.
• Record exact dates of sampling and relationship to suspected infection or rejection.

Assay result reporting — document Pleximmune IR and thresholds used

Report Pleximmune results as the immunoreactivity index (IR) and include the threshold used (examples reported: IR ≥1.1 post‑transplant; pre‑transplant IR ≥1.23) when presenting results to justify clinical decisions.

• Pleximmune IR thresholds reported in training/validation: post‑transplant IR ≥1.1 and pre‑transplant IR ≥1.23 predictive for rejection in pediatric LTx/ITx cohorts.
• Include IR value and whether it meets the specified threshold in clinical documentation.

Supporting documentation from studies — include biopsy pairing/serial dd‑cfDNA when applicable

When using dd‑cfDNA studies to support a diagnosis of rejection, include paired biopsy results or serial dd‑cfDNA measurements as supporting documentation because many studies correlated dd‑cfDNA with biopsy‑proven rejection.

• SNP‑based dd‑cfDNA study reported biopsy‑matched samples and used a pre‑specified cut‑off (>1%) to detect active rejection with high AUC.
• Record biopsy dates/results and corresponding dd‑cfDNA values when available to support interpretation.

Required assay documentation — record assay type, quantitative result and thresholds used

Providers must document the assay type, the quantitative result and thresholds applied (examples: QuantiFERON‑CMV reactive threshold ≥0.2 IU/mL; ImmuKnow ATP categories: <225, 225–525, ≥525 ng/mL) and timing relative to transplant or prophylaxis.

• QuantiFERON‑CMV reactive threshold commonly reported as ≥0.2 IU/mL.
• ImmuKnow ATP category cut‑points: low <225 ng/mL; intermediate 225–525 ng/mL; high ≥525 ng/mL.
• Document when the sample was taken relative to transplant and any prophylaxis changes.

Administrative note — policy history contains no provider authorization steps

Administrative policy history and notes do not prescribe provider authorization steps; follow the policy content and payer-specific administrative procedures.

• Policy history and additional information sections record review dates and administrative notes but do not define provider authorization workflow.

Denial triggers — claims with excluded codes/indications may be denied

Claims submitted with CPT/HCPCS/ICD‑10 codes listed as not covered for CPB indications may be denied if paired with excluded diagnosis codes or for experimental/investigational indications; ensure coding aligns with covered indications.

• Policy lists CPT/HCPCS codes and multiple ICD‑10 codes as not covered for the CPB‑listed indications (examples: B25.8 for CMV, codes for post‑transplant complications).
• Avoid submitting claims with excluded diagnosis codes for indications designated as experimental/investigational.

Denial risk — insufficient evidence for rejection‑risk use of ImmuKnow

Insufficient evidence supports ImmuKnow for management of transplant rejection or for identifying individual pre‑transplant rejection risk; use for those indications may be denied.

• Policy states there is insufficient evidence of ImmuKnow effectiveness for management of organ transplant rejection and for identifying individuals at risk for rejection prior to transplant.
• Provide alternative supporting clinical evidence if ordering for rejection‑related indications.

Denial risk — regulatory status of assay may affect coverage

Regulatory status can affect coverage: tests that are not FDA‑cleared (e.g., T‑SPOT.CMV as a laboratory‑developed test) may not meet payer coverage requirements without additional justification.

• T‑SPOT.CMV has not been cleared or approved by the FDA and is performed in a CLIA/CAP‑accredited lab.
• When ordering non‑FDA‑cleared assays, include laboratory accreditation and clinical rationale in authorization requests.

Authorization considerations — include comprehensive documentation to reduce denial risk

Because some assays lack explicit authorization language in the policy and may not be FDA‑cleared, include comprehensive clinical documentation to mitigate potential denial risk.

• Policy notes assays described have not been FDA‑cleared/approved in some cases and that no explicit authorization criteria are stated; thorough documentation may be required by payers.

Denial risk — indeterminate/invalid results affect interpretation and actionability

Indeterminate QuantiFERON‑CMV results were excluded in analyses and may limit actionability; document indeterminate or invalid results and consider repeat testing or alternative assays before basing management decisions.

• One study reported 3.4% indeterminate QuantiFERON‑CMV results which were excluded from analyses.
• Indeterminate/invalid results can affect the interpretability of assay‑guided decisions and potential coverage adjudication.

Administrative note — no additional authorization/denial criteria in these sections

No explicit authorization or denial criteria are present in the remaining administrative portions of the document; follow payer‑specific policies for claim adjudication.

• Administrative and reference sections do not provide additional authorization or denial criteria.

Monitoring protocols

Monitoring protocols in published studies typically include a baseline pre-transplant sample and multiple post-transplant samples (examples: days 7, 14, 21, 42 and months 3, 6, 12); document these time points when relevant to interpretation.

• List exact sampling schedule used and relation to clinical events (e.g., suspected infection or rejection).

When assays guide immunosuppression, serial measurements and documented stepwise adjustments are used

When assays are used to guide immunosuppression, serial measurements and documentation of pre-specified thresholds and stepwise adjustments are used in studies (for example ImmuKnow-directed tacrolimus changes and Pleximmune risk stratification).

• Document the thresholds that will trigger each management step and the intended magnitude of adjustment.

dd-cfDNA evaluation context

dd-cfDNA evaluation has been performed both as surveillance testing and with biopsy-paired samples; interpretation often requires correlation with biopsy and clinical data.

• If dd-cfDNA is used, provide biopsy results when available or serial dd-cfDNA trends to support clinical conclusions.

CENTER REQUIREMENTS — CLIA/CAP lab processing for high-complexity assays

T-SPOT.CMV is performed in a CLIA- and CAP-accredited laboratory; high-complexity assays should be processed in appropriately accredited centers.

• Confirm the testing laboratory's CLIA/CAP accreditation when ordering or documenting these assays.